|1.||Thom, Maria: 2 articles (01/2014 - 09/2009)|
|2.||Vinters, Harry V: 2 articles (12/2010 - 09/2009)|
|3.||Ellis, Matthew: 1 article (01/2014)|
|4.||Brooke-Ball, Hannah: 1 article (01/2014)|
|5.||Brandner, Sebastian: 1 article (01/2014)|
|6.||Sisodiya, Sanjay M: 1 article (01/2014)|
|7.||de Tisi, Jane: 1 article (01/2014)|
|8.||Eriksson, Sofia H: 1 article (01/2014)|
|9.||Liu, Joan Y W: 1 article (01/2014)|
|10.||Resnick, Trevor: 1 article (12/2010)|
|1.||Malformations of Cortical Development
11/01/2004 - "We conclude that patients with FCD type 1 and mMCD had a better outcome compared with those with more severe forms of cortical dysplasia. "
09/01/2009 - "Particular emphasis will be paid to the classification system for focal cortical dysplasias (FCD), which can be histopathologically distinguished as type I and II. Also mild forms of cortical malformations (mMCD) may be present, including heterotopic neurons in white matter location. "
11/01/2004 - "Distribution of histological subtypes differed in temporal and extratemporal localization, with a significantly higher extratemporal prevalence of FCD type 2. There was a tendency towards better postsurgical outcome related to the last follow-up visit in patients with more subtle abnormalities classified as mild malformations of cortical development (mMCD) (63% Engel Ia), FCD type 1a (67% Engel Ia) and FCD type 1b (55% Engel Ia) compared with patients with FCD type 2a (43% Engel Ia) and FCD type 2b (Taylor type) (50% Engel Ia). "
12/01/2010 - "A cohort of children with significant prenatal and perinatal brain injury and histologically proven mild malformations of cortical development (mMCD) or FCD was analyzed. "
11/01/1987 - "Disposition characteristics of mitomycin C-dextran conjugate in normal and tumor-bearing muscles of rabbits."
08/01/1987 - "Disposition and tumor localization of mitomycin C-dextran conjugates in mice."
04/01/1981 - "Antitumor activity of mitomycin C-dextran conjugate against various murine tumors."
08/01/1987 - "Therefore, anionic mitomycin C-dextran conjugates with a high molecular weight may be useful for tumor targeting in cancer chemotherapy."
11/01/1987 - "Disposition characteristics of the macromolecular prodrug of mitomycin C (MMC), mitomycin C-dextran conjugate (MMC-D), in normal and tumor (VX2 carcinoma)-bearing rabbit thigh muscles were studied using the in situ vascular perfusion technique. "
01/01/2014 - "Using results from WSA manual, we proposed a threshold value for the classification of mMCD II, where 78% of patients now classified with mMCD II were seizure-free at the second post-operatively follow up. "
11/01/2004 - "Considering the outcome at follow-up periods over 12 and 24 months, complete seizure-freedom was achieved significantly more often in patients with FCD type 1 and mMCD than with FCD type 2, and seizure reduction by less than 75% (Engel IV) occurred in more patients with FCD type 2a compared with the other subgroups. "
|4.||Colonic Neoplasms (Colon Cancer)
03/01/1992 - "Preparation and properties of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate."
02/01/1991 - "Tumor localization and in vivo antitumor activity of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate."
|1.||Drug Therapy (Chemotherapy)